β-linked Galactose, N-Acetyllactosamine (LacNAc) & Lewis x (Lex)-binding Lectin Production Service

β-linked Galactose, N-Acetyllactosamine (LacNAc) & Lewis x (Lex)-binding Lectin Production Service

Production of Lectin with High Efficiency and Value

With years of experience in developing and producing Recombinant Lectins, our production team has production expertise to provide clients with unique β-linked galactose, N-Acetyllactosamine (LacNAc) & Lewis x (Lex)-binding lectin production service. Depending on client needs and target lectin characteristics, CD BioGlyco provides a comprehensive production and analysis service, ranging from cloning, protein expression, purification, and characterization, to packaging.

β-linked Galactose, N-Acetyllactosamine (LacNAc) & Lewis x (Lex)-binding Lectin Production Service at CD BioGlyco

  • Production service
  • Primer design: The primer is designed to provide the client with the complete gene sequence of galactose-binding lectin by using two restriction enzymes as terminal restriction sites.
  • PCR amplification: We amplify DNA polymerase and detect the PCR products using agarose gel electrophoresis. Reaction conditions are tightly controlled at each step.
  • Vector construction: Our professional staff has extensive experience in vector construction.
  • Expression and purification: The recombinant plasmid is transformed into the host, induced expression in small amounts, purified by affinity adsorption, and detected using SDS-PAGE. After no error, the expression is largely induced and purified.
  • Analysis service

For purified target lectins, we provide some identification services, such as hemagglutination tests, differential scanning fluorescence detection of stability, etc.

Fig.1 Flow chart of recombinant lectin production. (CD BioGlyco)Fig.1 Flow chart of recombinant lectin production. (CD BioGlyco)

Publication

Paper Title: Galectin-4, a novel neuronal regulator of myelination

Journal: Glia

Published: 2012

IF: 5.984

Results: Recombinant galectin-4 (Gal-4) interferes with the growth and development process of oligodendrocytes (OLG) through carbohydrate interactions. The results showed that the number of myelin basic protein (MBP) positive cells treated with galectin-4 or C-terminal domain did not differ from the number of control cells treated with MBP positive vector. The release of endogenous Gal-4 correlated with myelination in cocultures. Both cortical and dorsal root ganglia (DRG) neurons release galectin-4, in vitro and in vivo, and both cortical DRG neurons release Gal-4. Since exposure to recombinant Gal-4 delays the maturation of OLG, the profiles confirm the involvement of Gal-4 in the OLG differentiation process.

Fig.2 Schematic representation of neuronal gal-4 involved in the OLG maturation process. (Stancic, et al., 2012)Fig.2 Schematic representation of neuronal gal-4 involved in the OLG maturation process. (Stancic, et al., 2012)

Advantages of Us

  • Multiple host expression systems, tags, and markers: We have multiple host Expression Systems, and the generated target lectins are both unlabeled with biotin, Fc, or His tags or fluorescent tags, to meet the various needs of clients.
  • We have a scalable production capacity to meet your needs when your research requires more proteins.

CD BioGlyco's team consists of a group of experienced and passionate scientists and engineers, who aim to constantly innovate and improve the quality of service. If you have any questions about Galactose-binding Lectin, our scientists and professional technical services team provide you with professional help at any time. Please feel free to contact us.

Reference

  1. Stancic, M.; et al. Galectin-4, a novel neuronal regulator of myelination. Glia. 2012, 60(6): 919-35.
This service is for Research Use Only, not intended for any clinical use.

Thanksgiving 2024

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0